The US cancer society has lowered the recommended age for bowl cancer screening from 50 to 45. This could benefit RHY in the future with their US GTM strategy.
A good summary of the RHY opportunity I found on Twitter "One thing $RHY has going for it is that it has a very low market cap ($19 million, $11m EV), compared to $9,6 billion for Exact Sciences, maker of a faecal colon cancer test. Therefore, if performance is maintained in larger prospective trials, the potential is very material"
RHY Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
